Zobrazeno 1 - 10 of 82 pro vyhledávání: '"Richard A. Kenney"'
1
Akademický článek
SON-1010: an albumin-binding IL-12 fusion protein that improves cytokine half-life, targets tumors, and enhances therapeutic efficacy
Autor: John K. Cini, Richard T. Kenney, Susan Dexter, Stephen J. McAndrew, Rukiye-Nazan Eraslan, Rich Brody, Darrel J. Rezac, Rebecca Boohaker, Suzanne E. Lapi, Pankaj Mohan
Publikováno v: Frontiers in Immunology, Vol 15 (2024)
BackgroundCytokines have been promising cancer immunotherapeutics for decades, yet only two are licensed to date. Interleukin-12 (IL-12) is a potent regulator of cell-mediated immunity that activates NK cells and interferon-γ (IFNγ) production. It
Externí odkaz: https://doaj.org/article/438bbbcb4fa04e72a0a4640f320246d0
Zobrazit plný text záznamu
2
Akademický článek
A phase I trial of SON-1010, a tumor-targeted, interleukin-12-linked, albumin-binding cytokine, shows favorable pharmacokinetics, pharmacodynamics, and safety in healthy volunteers
Autor: Richard T. Kenney, John K. Cini, Susan Dexter, Manuel DaFonseca, Justus Bingham, Isabelle Kuan, Sant P. Chawla, Thomas M. Polasek, Jason Lickliter, Philip J. Ryan
Publikováno v: Frontiers in Immunology, Vol 15 (2024)
BackgroundThe benefits of recombinant interleukin-12 (rIL-12) as a multifunctional cytokine and potential immunotherapy for cancer have been sought for decades based on its efficacy in multiple mouse models. Unexpected toxicity in the first phase 2 s
Externí odkaz: https://doaj.org/article/9baead1eb8e549ccaed6f20a613f9c70
Zobrazit plný text záznamu
3
Akademický článek
SON-1210 - a novel bifunctional IL-12 / IL-15 fusion protein that improves cytokine half-life, targets tumors, and enhances therapeutic efficacy
Autor: John K. Cini, Susan Dexter, Darrel J. Rezac, Stephen J. McAndrew, Gael Hedou, Rich Brody, Rukiye-Nazan Eraslan, Richard T. Kenney, Pankaj Mohan
Publikováno v: Frontiers in Immunology, Vol 14 (2023)
BackgroundThe potential synergy between interleukin-12 (IL-12) and IL-15 holds promise for more effective solid tumor immunotherapy. Nevertheless, previous clinical trials involving therapeutic cytokines have encountered obstacles such as short pharm
Externí odkaz: https://doaj.org/article/ec5b713791af4cd19df56d27a6cab5cc
Zobrazit plný text záznamu
4
Akademický článek
A Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1
Autor: Neeta Somaiah, Sant P. Chawla, Matthew S. Block, John C. Morris, Khanh Do, Joseph W. Kim, Mihaela Druta, Kamalesh K. Sankhala, Patrick Hwu, Robin L. Jones, Sacha Gnjatic, Seunghee Kim-Schulze, Kevin Tuballes, Mahlet Yishak, Hailing Lu, Adam Yakovich, Jan Ter Meulen, Michael Chen, Richard T. Kenney, Chet Bohac, Seth M. Pollack
Publikováno v: OncoImmunology, Vol 9, Iss 1 (2020)
Preclinical data suggest that a “prime-boost” vaccine regimen using a target-expressing lentiviral vector for priming, followed by a recombinant protein boost, may be effective against cancer; however, this strategy has not been evaluated in a cl
Externí odkaz: https://doaj.org/article/aeaf8cf7e6dc4867be463362683d875c
Zobrazit plný text záznamu
5
Abstract CT245: Clinical development of a novel form of interleukin-12 with extended pharmacokinetics
Autor: Sant P. Chawla, Victoria S. Chua, Erlinda M. Gordon, John Cini, Susan Dexter, Manual DaFonseca, Justus Bingham, Grantham W. Hogeland, Richard T. Kenney
Publikováno v: Cancer Research. 83:CT245-CT245
Recombinant interleukins (IL) have had limited clinical success due to inefficient tumor targeting and short pharmacokinetics (PK), requiring frequent dosing that leads to aberrant immunostimulation and toxicity. IL-12 is a promising cancer treatment
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0666448767977a6780297e6335c711c1
https://doi.org/10.1158/1538-7445.am2023-ct245
Zobrazit plný text záznamu
8
Abstract 4229: An innovative human platform for targeted delivery of bispecific interleukins to tumors
Autor: John K. Cini, Stephen J. McAndrew, Nick Evans, Lucie Janeckova, Maryam Ahmadi, Rukiye-Nazan Eraslan, Miglena G. Prabagar, Susan Dexter, Richard T. Kenney
Publikováno v: Cancer Research. 82:4229-4229
Combination approaches using stimulatory cytokines, checkpoint inhibitors, chemotherapy and/or radiation therapy are known to improve overall survival of cancer patients. Recombinant interleukins (IL) have had limited clinical success due to short ph
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::61350d47d043e158ac403c2a20145347
https://doi.org/10.1158/1538-7445.am2022-4229
Zobrazit plný text záznamu
10
A randomized multicenter phase II trial to evaluate the safety and efficacy of vaccination with folate receptor alpha (FRα) peptides admixed with GM-CSF as an adjuvant versus GM-CSF alone in patients with platinum-sensitive ovarian cancer (EOC)
Autor: Robert M. Wenham, Jason A. Konner, Matthew S. Block, Richard T. Kenney, Roisin E. O'Cearbhaill, James E. Potts, Gerald Garrett
Publikováno v: Journal of Clinical Oncology. 38:6040-6040
6040 Background: FRα is overexpressed on > 90% of high-grade EOC. We conducted a randomized double-blind multicenter phase II clinical trial to evaluate the safety and efficacy of TPIV200 (a multi-epitope FRα peptide vaccine admixed with GM-CSF adj
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::abe6f7fcbf65ba4569ce67486eb5e323
https://doi.org/10.1200/jco.2020.38.15_suppl.6040
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje